Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies.
about
Synaptic dysfunction and septin protein family members in neurodegenerative diseasesLow-dose add-on memantine treatment may improve cognitive performance and self-reported health conditions in opioid-dependent patients undergoing methadone-maintenance-therapy.Advances in the treatment of cognitive impairment in Parkinson's disease.Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.Neuropsychiatric Issues in Parkinson's Disease.Nondopaminergic treatments for Parkinson's disease: current and future prospects.Clinical Epidemiology, Evaluation, and Management of Dementia in Parkinson Disease.Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases.Norms for healthy adults aged 18-87 years for the Cognitive Drug Research System: An automated set of tests of attention, information processing and memory for use in clinical trials.Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.Profiling attention and cognition enhancing drugs in a rat touchscreen-based continuous performance test.Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives.Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine.NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.
P2860
Q27026829-A72F218C-AD08-496D-BFD4-8EBE95EA6068Q35622561-0A2AB3EA-7B6B-43F1-AEFA-284884120406Q38571668-2548433D-267D-4C62-84CF-4FBAB6D2A339Q38632327-D0B32DF0-5A2A-46CC-88A6-B08B6620182DQ38799051-C99292A7-EE99-428E-BDDB-42B530D90C99Q38845546-02F67002-8BEF-4833-9676-DBF6533ECDE7Q38863643-AD210036-6575-4F81-94B7-8299D03CC71BQ38998475-3085CDC9-1EE9-47F2-BA2D-0E185F1E9944Q40119367-5DA4F989-AD99-4C42-B80F-74D4074F7F89Q46391552-059E8F53-0D47-40E5-BC70-D7037C6274F9Q47655831-105C4C00-D4A3-4205-A2D5-0EF84346DCF5Q47673497-36C2D889-B3BE-4B3C-AF09-780B70AD80CDQ48834526-82717ACA-0A29-4F14-88B5-121850121E91Q53377510-89465A2F-DC32-416E-BA5F-88D53040A4F0Q55474333-088CA398-74D7-48FD-B203-C96D42C49B27
P2860
Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Memantine improves attention a ...... and dementia with Lewy bodies.
@en
Memantine improves attention a ...... and dementia with Lewy bodies.
@nl
type
label
Memantine improves attention a ...... and dementia with Lewy bodies.
@en
Memantine improves attention a ...... and dementia with Lewy bodies.
@nl
prefLabel
Memantine improves attention a ...... and dementia with Lewy bodies.
@en
Memantine improves attention a ...... and dementia with Lewy bodies.
@nl
P2860
P50
P356
P1476
Memantine improves attention a ...... and dementia with Lewy bodies.
@en
P2093
Keith A Wesnes
P2860
P356
10.1002/GPS.4109
P407
P577
2014-04-16T00:00:00Z